262 related articles for article (PubMed ID: 31653712)
21. Establishing
Fendler WP; Stuparu AD; Evans-Axelsson S; Lückerath K; Wei L; Kim W; Poddar S; Said J; Radu CG; Eiber M; Czernin J; Slavik R; Herrmann K
J Nucl Med; 2017 Nov; 58(11):1786-1792. PubMed ID: 28546332
[TBL] [Abstract][Full Text] [Related]
22. Influence of short-term dexamethasone on the efficacy of
Derlin T; Sommerlath Sohns JM; Schmuck S; Henkenberens C; von Klot CAJ; Ross TL; Bengel FM
Prostate; 2020 May; 80(8):619-631. PubMed ID: 32187729
[TBL] [Abstract][Full Text] [Related]
23. Elevated Body Mass Index Is Associated with Improved Overall Survival in Castration-Resistant Prostate Cancer Patients Undergoing Prostate-Specific Membrane Antigen-Directed Radioligand Therapy.
Hartrampf PE; Mihatsch PW; Seitz AK; Solnes LB; Rowe SP; Pomper MG; Kübler H; Bley TA; Buck AK; Werner RA
J Nucl Med; 2023 Aug; 64(8):1272-1278. PubMed ID: 37290794
[TBL] [Abstract][Full Text] [Related]
24. Early Experience of Rechallenge
Gafita A; Rauscher I; Retz M; Knorr K; Heck M; Wester HJ; D'Alessandria C; Weber WA; Eiber M; Tauber R
J Nucl Med; 2019 May; 60(5):644-648. PubMed ID: 30442756
[TBL] [Abstract][Full Text] [Related]
25. Delayed response after repeated
Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
[TBL] [Abstract][Full Text] [Related]
26. Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy.
Wrenger R; Jüptner M; Marx M; Zhao Y; Zuhayra M; Caliebe A; Osmonov D; Lützen U
BMC Urol; 2022 Jul; 22(1):96. PubMed ID: 35788220
[TBL] [Abstract][Full Text] [Related]
27. Results of a Prospective Phase 2 Pilot Trial of
Emmett L; Crumbaker M; Ho B; Willowson K; Eu P; Ratnayake L; Epstein R; Blanksby A; Horvath L; Guminski A; Mahon K; Gedye C; Yin C; Stricker P; Joshua AM
Clin Genitourin Cancer; 2019 Feb; 17(1):15-22. PubMed ID: 30425003
[TBL] [Abstract][Full Text] [Related]
28.
Bräuer A; Grubert LS; Roll W; Schrader AJ; Schäfers M; Bögemann M; Rahbar K
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1663-1670. PubMed ID: 28624848
[TBL] [Abstract][Full Text] [Related]
29. Molecular imaging and biochemical response assessment after a single cycle of [
Rosar F; Hau F; Bartholomä M; Maus S; Stemler T; Linxweiler J; Ezziddin S; Khreish F
Theranostics; 2021; 11(9):4050-4060. PubMed ID: 33754047
[No Abstract] [Full Text] [Related]
30. Repeated
Rathke H; Giesel FL; Flechsig P; Kopka K; Mier W; Hohenfellner M; Haberkorn U; Kratochwil C
J Nucl Med; 2018 Mar; 59(3):459-465. PubMed ID: 28798031
[TBL] [Abstract][Full Text] [Related]
31. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
Rahbar K; Ahmadzadehfar H; Kratochwil C; Haberkorn U; Schäfers M; Essler M; Baum RP; Kulkarni HR; Schmidt M; Drzezga A; Bartenstein P; Pfestroff A; Luster M; Lützen U; Marx M; Prasad V; Brenner W; Heinzel A; Mottaghy FM; Ruf J; Meyer PT; Heuschkel M; Eveslage M; Bögemann M; Fendler WP; Krause BJ
J Nucl Med; 2017 Jan; 58(1):85-90. PubMed ID: 27765862
[TBL] [Abstract][Full Text] [Related]
32. Prognostic implications of dual tracer PET/CT: PSMA ligand and [
Michalski K; Ruf J; Goetz C; Seitz AK; Buck AK; Lapa C; Hartrampf PE
Eur J Nucl Med Mol Imaging; 2021 Jun; 48(6):2024-2030. PubMed ID: 33336265
[TBL] [Abstract][Full Text] [Related]
33. [PSMA-targeted radioligand therapy in prostate cancer].
Heck MM; Retz M; Tauber R; Knorr K; Kratochwil C; Eiber M
Urologe A; 2017 Jan; 56(1):32-39. PubMed ID: 27885457
[TBL] [Abstract][Full Text] [Related]
34. [PSMA radioligand therapy in patients with advanced prostate cancer].
Bögemann M; Herrmann K; Radtke JP; Rahbar K
Urologe A; 2020 Jun; 59(6):680-686. PubMed ID: 32333064
[TBL] [Abstract][Full Text] [Related]
35. Clinical Outcomes of
Barber TW; Singh A; Kulkarni HR; Niepsch K; Billah B; Baum RP
J Nucl Med; 2019 Jul; 60(7):955-962. PubMed ID: 30683770
[No Abstract] [Full Text] [Related]
36. Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
Kim YJ; Kim YI
Clin Nucl Med; 2018 Oct; 43(10):728-734. PubMed ID: 30059428
[TBL] [Abstract][Full Text] [Related]
37. Albumin-Binding and Conventional PSMA Ligands in Combination with
Tschan VJ; Busslinger SD; Bernhardt P; Grundler PV; Zeevaart JR; Köster U; van der Meulen NP; Schibli R; Müller C
J Nucl Med; 2023 Oct; 64(10):1625-1631. PubMed ID: 37442604
[TBL] [Abstract][Full Text] [Related]
38. Factors predicting biochemical response and survival benefits following radioligand therapy with [
Manafi-Farid R; Harsini S; Saidi B; Ahmadzadehfar H; Herrmann K; Briganti A; Walz J; Beheshti M
Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4028-4041. PubMed ID: 33677734
[TBL] [Abstract][Full Text] [Related]
39. Any decline in prostate-specific antigen levels identifies survivors scheduled for prostate-specific membrane antigen-directed radioligand therapy.
Hartrampf PE; Weinzierl FX; Seitz AK; Kübler H; Essler M; Buck AK; Werner RA; Bundschuh RA
Prostate; 2022 Oct; 82(14):1406-1412. PubMed ID: 35860909
[TBL] [Abstract][Full Text] [Related]
40. Response Assessment and Prediction of Progression-Free Survival by
Khreish F; Wiessner M; Rosar F; Ghazal Z; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
